TCRX icon

TScan Therapeutics

2.37 USD
-0.03
1.25%
At close Jan 21, 4:00 PM EST
1 day
-1.25%
5 days
-13.19%
1 month
-21.26%
3 months
-55.03%
6 months
-65.60%
Year to date
-23.30%
1 year
-54.60%
5 years
-77.43%
10 years
-77.43%
 

About: TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

Employees: 199

0
Funds holding %
of 6,823 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

91% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 11

33% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 18

25% more funds holding in top 10

Funds holding in top 10: 4 [Q2] → 5 (+1) [Q3]

11% more funds holding

Funds holding: 80 [Q2] → 89 (+9) [Q3]

0.13% more ownership

Funds ownership: 85.84% [Q2] → 85.97% (+0.13%) [Q3]

15% less capital invested

Capital invested by funds: $244M [Q2] → $209M (-$35.5M) [Q3]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$11
364%
upside
Avg. target
$13
449%
upside
High target
$15
533%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Andrew Fein
34% 1-year accuracy
114 / 339 met price target
533%upside
$15
Buy
Reiterated
11 Dec 2024
Needham
Gil Blum
15% 1-year accuracy
26 / 169 met price target
364%upside
$11
Buy
Reiterated
11 Dec 2024

Financial journalist opinion

Based on 3 articles about TCRX published over the past 30 days

Neutral
Zacks Investment Research
1 week ago
Here's Why TScan Therapeutics (TCRX) is Poised for a Turnaround After Losing -5.63% in 4 Weeks
The heavy selling pressure might have exhausted for TScan Therapeutics (TCRX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Here's Why TScan Therapeutics (TCRX) is Poised for a Turnaround After Losing -5.63% in 4 Weeks
Neutral
GlobeNewsWire
3 weeks ago
TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium
WALTHAM, Mass., Dec. 26, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that it has entered into a securities purchase agreement with Lynx1 Capital Management LP (Lynx1) and an investment fund advised by Lynx1 for the sale of approximately $30 million of pre-funded warrants to purchase up to an aggregate of 7,500,000 shares of its voting common stock at a price of $4.00 per pre-funded warrant, each exercisable to purchase one share of voting common stock at an exercise price of $0.0001 per share, representing a premium of 37% to the last closing price of TScan Therapeutics' common stock, and a 34% premium over the 10-day volume weighted average closing price. The financing is expected to close on or about December 27, 2024, subject to customary closing conditions.
TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium
Neutral
GlobeNewsWire
4 weeks ago
TScan Therapeutics Refinances Existing Convertible Debt Facility with Term Loan for up to $52.5 Million from Silicon Valley Bank
New non-dilutive structure replaces existing convertible facility maturing in 2026, and extends loan maturity to 2029 New non-dilutive structure replaces existing convertible facility maturing in 2026, and extends loan maturity to 2029
TScan Therapeutics Refinances Existing Convertible Debt Facility with Term Loan for up to $52.5 Million from Silicon Valley Bank
Neutral
GlobeNewsWire
1 month ago
TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA™ Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition
To date, event-free survival strongly favors the treatment arm (HR=0.30; p=0.04), and treatment-arm patients trend towards lower probability of relapse (HR=0.28; p=0.14)
TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA™ Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition
Neutral
GlobeNewsWire
1 month ago
TScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive Years
WALTHAM, Mass., Dec. 05, 2024 (GLOBE NEWSWIRE) --  TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced it has been named one of the Top Places to Work in Massachusetts in the 17th annual, employee-based survey from The Boston Globe. The 2024 Top Places to Work issue was published online at Globe.com/TopPlaces and will appear in Globe Magazine on Sunday, December 8, 2024.
TScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive Years
Neutral
GlobeNewsWire
1 month ago
TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Heme Development Strategy
Company to also provide an update on PLEXI-T™ Phase 1 solid tumor trial Company to also provide an update on PLEXI-T™ Phase 1 solid tumor trial
TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Heme Development Strategy
Negative
Zacks Investment Research
2 months ago
TScan Therapeutics, Inc. (TCRX) Reports Q3 Loss, Misses Revenue Estimates
TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.24 per share a year ago.
TScan Therapeutics, Inc. (TCRX) Reports Q3 Loss, Misses Revenue Estimates
Positive
Zacks Investment Research
2 months ago
TScan Therapeutics (TCRX) Soars 7.6%: Is Further Upside Left in the Stock?
TScan Therapeutics (TCRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
TScan Therapeutics (TCRX) Soars 7.6%: Is Further Upside Left in the Stock?
Neutral
GlobeNewsWire
2 months ago
TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition
All TSC-treated patients were relapse-free and MRD negative as of data cutoff TSC-100 and TSC-101 demonstrate the potential to reduce relapse rates and increase relapse-free survival in patients with AML, ALL, or MDS undergoing allogeneic HCT with reduced intensity conditioning Company to host virtual KOL event featuring Ran Reshef, M.D., M.Sc., on Tuesday, December 10, at 8:00 a.m.
TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition
Neutral
GlobeNewsWire
3 months ago
TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting
WALTHAM, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced the acceptance of three abstracts for poster presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting being held November 6 – 10 in Houston, TX and virtually.
TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting
Charts implemented using Lightweight Charts™